Tremelimumab
http://dbpedia.org/resource/Tremelimumab an entity of type: Thing
Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. Tremelimumab was approved for unresectable hepatocellular carcinoma medical use in the United States in October 2022.
rdf:langString
rdf:langString
Tremelimumab
xsd:integer
9133652
xsd:integer
1122678040
rdf:langString
None
xsd:integer
6500
rdf:langString
Fab fragment of tremelimumab binding CTLA-4 . From PDB entry .
xsd:integer
745013
rdf:langString
none
rdf:langString
DB11771
xsd:integer
9974
rdf:langString
D06657
rdf:langString
Rx-only
xsd:integer
1726
xsd:integer
2026
xsd:integer
52
rdf:langString
u
rdf:langString
tremelimumab-actl, ticilimumab, CP-675, CP-675,206
rdf:langString
Imjudo
rdf:langString
mab
rdf:langString
QEN1X95CIX
rdf:langString
changed
xsd:integer
470612724
rdf:langString
changed
rdf:langString
Tremelimumab, sold under the brand name Imjudo, is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. Tremelimumab was approved for unresectable hepatocellular carcinoma medical use in the United States in October 2022.
rdf:langString
Tremelimumab
xsd:integer
8462
rdf:langString
mab
xsd:nonNegativeInteger
12428
rdf:langString
Imjudo
xsd:string
745013-59-6
xsd:string
DB11771
xsd:string
QEN1X95CIX
xsd:string
D06657